The Historical Return of Opiates

This thread follows the book’s historical argument that successive generations repeatedly forget how easily medical opioids can create dependence.

increasingBearing stren­gth in each eventdecreasing

Morphine’s Discovery

Morphine’s Discovery A powerful compound Friedrich Sertürner isolated morphine from opium and observed its strong effects and dangerous aftermath. His account of dependence and withdrawal anticipated problems that later practitioners would repeatedly rediscover. A warning neglected The new compound offered medical power, but warnings did not prevent enthusiasm from outrunning caution. The story established an early pattern: a novel treatment could be celebrated before its risks were understood. The book uses this history to challenge the belief that the modern crisis was wholly unprecedented. Its recurring lesson is that scientific and social memory often fails to restrain commercial optimism.

A Medical Confidence

A Medical Confidence A new technique The hypodermic needle made it possible to deliver morphine quickly. Some doctors believed injection would avoid addiction, a confidence that echoed later claims about safer ways to administer opioids. Dependence after war Morphine was widely available to wounded soldiers, and many veterans became dependent. Their circumstances complicated the distinction between medical patients and people later labeled as criminals. The episode shows how therapeutic use can become a route into addiction without a person setting out to misuse a drug. It also reveals how social judgments change when the identity of the user changes.

Heroin as a Cure

Heroin as a Cure A commercial promise Bayer promoted heroin as a safe, nonaddictive remedy for coughs and other conditions. Its confident marketing repeated the belief that a new opioid could escape the liabilities of older ones. A delayed reversal As evidence of dependence mounted, medical and political opinion shifted. The Harrison Act restricted narcotics, and heroin manufacture was later prohibited, but the drug’s early availability had already widened exposure. The history makes the later marketing of OxyContin feel less like an isolated mistake than a familiar cycle. Public memory fades; the promise of a new drug returns.

The OxyContin Reprise

The OxyContin Reprise Reassurance returns Purdue Pharma promoted OxyContin’s controlled-release design as a reason to believe it was less prone to misuse. That reassurance drew on limited evidence and became a powerful message in medical education and sales work. Warnings repeat Art Van Zee and other local observers documented rapid misuse and addiction. As with earlier opiate crises, the people closest to the harm struggled to persuade institutions that the emerging pattern required a wider response. The modern epidemic unfolded amid sophisticated regulation and medicine, yet old assumptions persisted. The title’s “United States of Amnesia” describes a recurring failure to retain hard-won lessons.

A Long Memory

A Long Memory History as warning Researchers and advocates connected the contemporary epidemic to earlier waves of opium, morphine, and heroin dependence. These parallels did not make the present crisis identical, but they revealed how familiar its promises and failures were. Memory as prevention The historical record could inform prescribing, treatment, and public policy only if decision-makers took its lessons seriously. The book frames remembrance as a practical responsibility, not an academic exercise. The closing argument asks readers to resist treating each outbreak as surprising or confined to someone else. History matters because communities repeatedly inherit consequences they might have anticipated.

1810, when Friedrich Sertürner warned about morphine

1853–the American Civil War era, as morphine injection became common

1897–1914, as Bayer marketed heroin and lawmakers restricted narcotics

1995–2001, as OxyContin was approved, promoted, and challenged

2016–2017, as advocates compared the crisis with earlier drug waves